Back to News
Market Impact: 0.15
Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's Disease
Source: Nasdaq
Healthcare & Biotech
Palisade Bio presented new clinical and translational findings on investigational drug PALI-2108 at UEG Week 2026 in Barcelona. The provided article text ends before reporting the findings or any numerical results, so their implications cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
PALI0.45
More News
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Why is Intuitive Surgical stock sliding today?
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Alpha Teknova stock tumbles on public offering announcement
- Disc Medicine prices $450 million stock offering at $75/share
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle